Last reviewed · How we verify
Xylometazoline Nasal
At a glance
| Generic name | Xylometazoline Nasal |
|---|---|
| Also known as | Otrivin® 0.05 % with Registration number: VN-15558-12, NasenSpray-ratiopharm Erwachsene (adults) |
| Sponsor | Anabio R&D |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Proponent Solution - Nasal Spray (PSNS) With Salt Water for Treating Nasal Congestion Symptoms in Adults With Rebound Nasal Congestion While Weaning From Nasal Decongestant Sprays (NA)
- Adrenaline Nasal Pack vs Xylometazoline Nasal Drops During Nasotracheal Intubation (PHASE2, PHASE3)
- Cocaine, Lidocaine/xylometazoline and Saline for Nasal Analgesia (PHASE3)
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media (NA)
- Otrivine: Quality of Life (QoL) Impact in a Real-World Setting (PHASE4)
- Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis (NA)
- Nasal Breathing and Physical Capacity (PHASE4)
- Xylometazoline and Cocaine for Nasal Vasoconstriction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |